Freenome (FRNM) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
29 Aug, 2026Executive summary
Incorporated on March 22, 2024, as a blank check company to pursue a business combination; no operating revenues to date, only interest income from IPO proceeds held in trust.
Completed IPO on June 13, 2024, raising $86.25 million from 8,625,000 Class A shares, including full over-allotment exercise.
Simultaneously sold 286,250 private placement shares for $2.86 million to the sponsor.
Net income for Q2 2024 was $102,875, driven by interest income and unrealized gains, offset by operating costs.
Financial highlights
As of June 30, 2024: $1.29 million in cash outside the trust account and $86.46 million in U.S. Treasury securities in the trust account.
Net income for Q2 2024: $102,875; for the period from inception through June 30, 2024: $87,478.
Operating costs for Q2 2024: $106,554; interest income: $202,332; unrealized gain: $7,097.
Transaction costs for IPO totaled $4.81 million, including $1.73 million cash underwriting fee and $3.45 million deferred underwriting fee.
Outlook and guidance
Intends to use IPO and private placement proceeds to complete a business combination by June 13, 2026.
No assurance of completing a business combination within the required period; failure to do so will result in liquidation.
Latest events from Freenome
- IPO filing details a well-funded, AI-driven cancer screening innovator with FDA approval and major partnerships.FRNM
Registration filing - SPAC raised $86.25M, reports $1.91M net income, must acquire or liquidate in 24 months.FRNM
Q4 2024 - SPAC holds $91.9M in trust, targets Freenome merger in 2026, but faces going concern risks.FRNM
Q4 2025 - Vote sought to extend business combination deadline by one year, with redemption rights offered.FRNM
Proxy filing - Q1 2025 net income reached $678,555, with $90.6M in assets and ongoing exposure to global market risks.FRNM
Q1 2025 - Q1 2026 saw a net loss and rising expenses as the company pursues the Freenome merger.FRNM
Q1 2026 - Q2 2025 net income reached $754,847, with ongoing risks tied to business combination completion.FRNM
Q2 2025 - Vote sought to extend merger deadline by one year; redemption rights and board support highlighted.FRNM
Proxy filing - Q3 net income reached $981,482, with all proceeds held in trust pending a business combination.FRNM
Q3 2024